BioLargo’s patented water treatment technology designed for per- and poly-fluoroalkyl substances (PFAS), called the BioLargo Aqueous Electrostatic Concentrator (AEC) is being prepped for its first field demonstration pilots and commercial trials. The technology, which works by using electrolysis to extract PFAS molecules from water and deposit them onto special membranes, boasts better power efficiency, greater specificity for PFAS, extremely high (99.9%+) removal efficiency, and minimal generation of PFAS-laden waste.
Recently our technology was featured in an article by Global Water Intelligence, a leader in market research and technology expertise in the water industry as an “emerging solution” for the PFAS threat. The article, which was in their popular “CTO Roundup Edition”, can be found here: https://www.globalwaterintel.com/global-water-intelligence-magazine/22/5/market-map/pfas-treatment-market-concentrates-on-waste-reduction-and-total-destruction
We are pleased to see our technology being highlighted by recognized thought-leaders in the area of advanced water treatment. As the technology rolls out in its first trials and commercial deployments, articles such as this one will be valuable tools to spread the word about how the BioLargo AEC has the potential to make PFAS treatment more affordable and environmentally friendly everywhere.
Some excerpts from the article include:
“Technology company BioLargo has developed a system that purportedly helps reduce the residuals issue. Its technology exploits the polarity of PFAS molecules, by separating two chambers with a membrane. Each chamber contains an oppositely charged electrode, which pulls the PFAS onto the membrane, where it stays bound. The key benefit to BioLargo’s technology, which is entering the commercial trialling stage, is how little wasted membrane is produced – the company claims it can treat 1 million gallons of water to 70ppt of PFAS with only 12g of membrane material. This produces far less waste for utilities or industrial users to deal with.”
“While sample processing can be expedited by paying a premium for two- to three-day turnaround, laboratories in the US are inundated and there remains a gap in the market for methods of delivering rapid results. “The technology for monitoring PFAS has not developed as fast as the regulations are developing,” observed Tonya Chandler, director of strategic marketing and business development at BioLargo.”